Vyfemla (NORETHINDRONE AND ETHINYL ESTRADIOL)
Vyfemla (NORETHINDRONE AND ETHINYL ESTRADIOL) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Vyfemla; Generic name: NORETHINDRONE AND ETHINYL ESTRADIOL; Manufacturer: Lupin Pharmaceuticals, Inc..
| Brand name | Vyfemla |
|---|---|
| Generic name | NORETHINDRONE AND ETHINYL ESTRADIOL |
| Manufacturer | Lupin Pharmaceuticals, Inc. |
| Used for | INDICATIONS AND USAGE Oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. TABLE 1 LOWEST EXPECTED AND TYPICAL FAILURE RATES DURING THE FIRST YEAR OF CONTINUOUS USE OF A METHOD % of Women Experiencing an Accidental Pregnancy in the First Year of C |
| Dosage | DOSAGE AND ADMINISTRATION The following is a summary of the instructions given to the patient in the " HOW TO TAKE THE PILL " section of the DETAILED PATIENT PACKAGE LABELING . The patient is given instructions in five (5) categories: IMPORTANT POINTS TO REMEMBER: The patient is told (a) that she should take one pill every day at the same time, (b) many women have spotting or light bleeding or gastric distress during the first one to three cycles, (c) missing pills can also cause spotting or lig |
| Warnings | WARNINGS Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke. The use of oral contraceptives is associated with increased risk of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=175ce5c4-d332-4c97-a0b8-10821dc813ef |